Advertisement

NDV Strain AF2240 Induces Apoptosis in Leukemia Cells

September, 09, 2024 | Leukemia

KEY TAKEAWAYS

  • The study aimed to assess apoptosis and morphological changes in WEHI 3B leukemia cells treated with NDV.
  • The results showed that NDV strain AF2240 induces apoptosis and structural changes in WEHI 3B leukemia cells.

Rola Ali-Saeed and the team aimed to explore the effects of Newcastle Disease Virus (NDV) strain AF2240 on myelomonocytic leukemia cells. Leukemia is a hematologic malignancy originating from abnormal leukocyte proliferation. NDV, an avian paramyxovirus, has shown potential as an oncolytic agent due to its tumor-selective cytotoxicity.

Researchers examined morphological changes and apoptosis induction in the WEHI 3B leukemia cell line following treatment with NDV strain AF2240. They used scanning electron microscopy and transmission electron microscopy techniques to observe these changes, along with fluorescence microscopy to identify early apoptosis 6 hours post-inoculation.

The results demonstrated that NDV strain AF2240 significantly altered the morphology of the WEHI 3B cells and reduced cell viability. The early apoptotic changes were observable as early as 6 hours after treatment initiation, confirmed through fluorescence microscopy.

The study concluded that NDV strain AF2240 induced apoptosis and notable structural alterations in the WEHI 3B leukemia cell line, providing insights into its potential as a virotherapy for leukemia treatment.

No funding information was given.

Source: https://pubmed.ncbi.nlm.nih.gov/39342575/

Ali-Saeed R, Alabsi AM, Al-Garadi MA, et al. (2024). “Ultrastructure Microscopic Characterization of Apoptosis in Myelomoncytic Leukemia Cell Line Treated with Velogenic Viscerotropic Newcastle Disease Virus Strain AF 2240.” Asian Pac J Cancer Prev. 2024;25(9):2991-2998. Published 2024 Sep 1. doi:10.31557/APJCP.2024.25.9.2991

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy